Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda to Buy Out T-Cell Engager Specialist Maverick for US$525 Million
March 11, 2021
- Nichi-Iko Drug Supply Delayed as Customers Flock to Place Orders
March 10, 2021
- 70% of Major Products Fall Victim to Off-Year Drug Re-Pricing: Jiho Tally
March 10, 2021
- JCR Terminates Temcell Development for Epidermolysis Bullosa
March 10, 2021
- Top-Tier Drug Makers Face 2-4% Cuts, Mid-Sized Firms 6-8% in Japan’s First Off-Year Re-Pricing: Tally
March 9, 2021
- Top-3 Generic Makers Hit with Average 9.8% Price Cut in Off-Year Revision: Jiho Tally
March 9, 2021
- Rohto Kicks Off Japan PIIa of JAK Inhibitor Delgocitinib for Dry Eye Symptoms
March 9, 2021
- Takeda Aims for Mid-Teens Annual Growth in Japan Oncology Biz: Exec
March 8, 2021
- Viatris Rolls Out 3 Follow-On AGs for Norvasc, Cardenalin, Relpax
March 8, 2021
- Japan Ethical Drug Sales Down 5.3% in January: Crecon
March 8, 2021
- Sumitomo Dainippon Ditches Napabucasin, 27 Billion Yen Impairment Loss to Be Incurred in FY2021
March 8, 2021
- Takeda Submits NDA for Moderna Vaccine in Japan
March 5, 2021
- Nichi-Iko’s Shipment Halt for 9 APIs Was Due to Biz Suspension
March 5, 2021
- Takeda Takes Back Rare Epilepsy Drug in Revised Deal with Ovid
March 5, 2021
- JCR to Build New Manufacturing Facility for COVID-19 Vaccine
March 5, 2021
- Alesion Top-Selling Drug in February: Encise
March 5, 2021
- Mitsubishi Tanabe Aims for Growth with Global Hopefuls in Pipeline: New Biz Plan
March 5, 2021
- J-TEC Now Consolidated Subsidiary of Teijin
March 4, 2021
- Nichi-Iko Chief Apologizes for GMP Violations, but Draws Clear Distinction from Kobayashi Kako Case
March 4, 2021
- Mitsubishi Tanabe to Launch US Research Center for CNS Drug Discovery
March 4, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…